EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group

Muneaki Shimada iD, Kosuke Yoshihara iD, Terumi Tanigawa iD, Hiroyuki Nomura iD, Junzo Hamanishi iD, Satoe Fujiwara iD, Hiroshi Tanabe iD, Hiroaki Kajiyama iD, Masaki Mandai iD, Daisuke Aoki iD, Takayuki Enomoto iD, Aikou Okamoto iD

Journal of Gynecologic Oncology · 2023

DOI: 10.3802/jgo.2023.34.e62 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Gynecologic Oncology, 2023. Verfasst von Muneaki Shimada und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of new treatments for gynecological malignancies has been conducted mainly through collaborative international phase III trials led by the United States and Europe. The survival outcomes of many gynecological malignancies have greatly improved as a result. Recent large-scale genome-wide association studies have revealed that drug efficacy and adverse event profiles are not always uniform. Thus, it is important to validate new treatment options in each country to safely and efficiently provide newly developed treatment options to patients with gynecological malignancies. The Japanese Gynecologic Oncology Group (JGOG) is conducting 5 cohort studies (JGOG 3026, 3027, 3028, 3030, and 3031) to establish real-world data (RWD) of poly(ADP-ribose) polymerase (PARP) inhibitor use in patients with advanced or recurrent epithelial ovarian cancer. The RWD constructed will be used to provide newly developed PARP inhibitors for women with advanced or recurrent ovarian cancer in a safer and more efficient manner as well as to develop further treatment options. In 2022, The JGOG, Korean Gynecologic Oncology Group, Chinese Gynecologic Cancer Society, and Taiwanese Gynecologic Oncology Group established the East Asian Gynecologic Oncology Trial Group to collaborate with East Asian countries in clinical research on gynecologic malignancies and disseminate new knowledge on gynecologic malignancies from Asia. The JGOG will conduct a collaborative integrated analysis of the RWD generated from Asian countries and disseminate real-world clinical knowledge regarding new treatment options that have been clinically implemented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Ovarian EpithelialOvarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsFemaleHumansEast Asian PeopleGenital Neoplasms, FemaleGenome-Wide Association StudyPoly(ADP-ribose) Polymerases

Stichwörter der Autor:innen

Epithelial Ovarian CancerPARP InhibitorsPoly(ADP-ribose) PolymerasesReal-world Data

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
  • Tohoku University Advanced Research Center for Innovations in Next-Generation Medicine, Sendai, Japan. muneaki.shimada.b7@tohoku.ac.jp.
  • Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Chuo, Japan.
  • Department of Gynecology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Toyoake, Japan.
  • Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan.

ORCID-Profile: Muneaki Shimada, Kosuke Yoshihara, Terumi Tanigawa, Hiroyuki Nomura, Junzo Hamanishi, Satoe Fujiwara, Hiroshi Tanabe, Hiroaki Kajiyama, Masaki Mandai, Daisuke Aoki, Takayuki Enomoto, Aikou Okamoto

Zitieren

APA

Shimada, M., Yoshihara, K., Tanigawa, T., Nomura, H., Hamanishi, J., Fujiwara, S., Tanabe, H., Kajiyama, H., Mandai, M., Aoki, D., Enomoto, T., & Okamoto, A. (2023). An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2023.34.e62

Vancouver

Shimada M, Yoshihara K, Tanigawa T, Nomura H, Hamanishi J, Fujiwara S, et al. An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group. Journal of Gynecologic Oncology. 2023. doi:10.3802/jgo.2023.34.e62

BibTeX
@article{Shimada2023,
  author = {Shimada, Muneaki and Yoshihara, Kosuke and Tanigawa, Terumi and Nomura, Hiroyuki and Hamanishi, Junzo and Fujiwara, Satoe and Tanabe, Hiroshi and Kajiyama, Hiroaki and Mandai, Masaki and Aoki, Daisuke and Enomoto, Takayuki and Okamoto, Aikou},
  title = {An attempt to establish real-world databases of poly(ADP-ribose) polymerase inhibitors for advanced or recurrent epithelial ovarian cancer: the Japanese Gynecologic Oncology Group},
  journal = {Journal of Gynecologic Oncology},
  year = {2023},
  doi = {10.3802/jgo.2023.34.e62}
}
Kostenlos starten →